How effective is stem cell therapy for cerebral palsy?
Stem cell therapy for cerebral palsy (CP) has shown improvements in motor function and daily activities in some patients in clinical research, with a reassuring short-term safety profile.

The best evidence for umbilical cord mesenchymal stem cells (MSCs) comes from a randomized, double-blind, placebo-controlled trial in children aged 2 to 12, in which those who received intravenous (IV) umbilical cord MSCs plus rehabilitation improved more in gross motor function and activities of daily living than those who received placebo plus rehabilitation, with differences that appeared about 6 months after treatment. A meta-analysis of randomized trials also found statistically significant motor gains. Results vary: some children improve meaningfully, others more modestly. At Stem Cell Mexico, CP protocols use only allogeneic MSCs from Wharton's jelly of the umbilical cord, as a complement to rehabilitation.
This guide explains how effectiveness is measured in CP, what the studies found in detail, which factors seem to influence results and how families can track progress objectively.
How effectiveness is measured in CP
Because CP affects each person differently, researchers use standardized tools to measure change:
- Gross Motor Function Measure (GMFM-66 or GMFM-88): evaluates lying, rolling, sitting, crawling, standing, walking, running and jumping. It is the most commonly used outcome in CP trials.
- Gross Motor Function Classification System (GMFCS): classifies severity from level I to V. It is mostly stable over time and is used to describe participants rather than measure small changes.
- Activities of daily living (ADL) scales and the Pediatric Evaluation of Disability Inventory (PEDI): measure self-care, mobility and social function in daily life.
- Modified Ashworth Scale: measures muscle tone and spasticity.
- Fine motor, speech, cognitive and quality-of-life assessments: used in some studies.
An improvement on a scale is meaningful only if it is larger than the change expected from growth, development and therapy alone. This is why controlled trials, which compare treated patients with similar patients who did not receive cells, are essential.
What the studies found
IV umbilical cord MSCs: randomized controlled trial
- Publication: Stem Cell Research & Therapy, 2020.
- Participants: 39 children aged 2 to 12 years with CP completed the study.
- Design: randomized, double-blind, placebo-controlled; all children received rehabilitation.
- Treatment: four IV infusions of umbilical cord MSCs at weekly intervals, or placebo.
- Results: the MSC group showed greater improvement in gross motor function (GMFM), which was not evident until 6 months after treatment and was maintained at 12 months. Activities of daily living improved more in the MSC group at 3, 6 and 12 months, and a comprehensive function assessment showed greater gains at 3 and 6 months.
- Safety: no serious adverse events; temporary fever, respiratory infections and diarrhea occurred at similar rates in both groups.
Meta-analysis of randomized trials
- Publication: World Journal of Stem Cells, 2019.
- Data: five randomized controlled trials, 282 patients.
- Results: statistically significant improvement in gross motor function with stem cell therapy compared with standard care; serious adverse events rare and similar between groups.
Cord blood in young children
- Publication: Stem Cells Translational Medicine, 2017 (Duke University).
- Findings: IV infusions of autologous cord blood were well tolerated; children who received higher doses showed more motor improvement at one year, along with changes in brain connectivity on imaging.
- Relevance: this study used a different product (the child's own cord blood), which is not used at Stem Cell Mexico. It is useful because it suggests that dose may influence outcomes.
Reviews of umbilical-cord-derived cells
More recent systematic reviews focused on umbilical-cord-derived cells in CP report a similar picture: acceptable safety, motor improvements in many studies and considerable variability in protocols and results. They consistently recommend larger, well-designed trials with longer follow-up.
Why results take time
In the randomized trial described above, differences in gross motor function between groups did not appear until about 6 months after treatment. This pattern is consistent with the proposed mechanism of MSCs: rather than replacing brain tissue, they may create a more favorable environment for the nervous system to adapt, and the child then needs time and practice to turn that potential into new skills. Families should therefore avoid judging results in the first weeks. Early changes, such as better sleep or energy, may be reported, but they are not reliable indicators of long-term benefit.
What improvement looks like in practice
In the context of CP, an improvement might mean:
- A child who could sit with support begins to sit independently for longer periods.
- A child who walks with a walker gains endurance or needs less assistance.
- Better hand use for feeding or play.
- Reduced spasticity that makes dressing, positioning or hygiene easier for caregivers.
For some families, these changes matter a great deal. For others, they may fall short of expectations. Discussing which specific changes would be meaningful for your child helps define realistic goals.
Factors that seem to influence effectiveness
- Age: most trials have included young children, and some data suggest earlier treatment may be associated with greater gains, likely because of greater neuroplasticity.
- Severity: children with milder to moderate CP (GMFCS levels I to III) may show more measurable motor changes on standard scales, although families of children with more severe CP may value improvements in comfort, tone or engagement.
- Dose: studies suggest that cell dose, adjusted to body weight, may matter.
- Number of infusions: some protocols use repeated infusions; the schedule is defined individually.
- Rehabilitation intensity: gains in trials occurred alongside rehabilitation, and therapy appears to be an important partner of cell therapy.
- Associated conditions: uncontrolled seizures, poor nutrition and frequent respiratory infections can limit progress.
How Stem Cell Mexico measures and reports results
- Cells: allogeneic MSCs from Wharton's jelly of donated umbilical cords, obtained after healthy, full-term births with informed consent and donor screening. No autologous cells, cord blood or other cell sources are used.
- Laboratory: produced in a COFEPRIS-licensed laboratory under Good Manufacturing Practice standards, with quality and safety testing before release.
- Baseline: we encourage families to bring recent assessments from their therapists, ideally including GMFM scores, and videos of current abilities.
- Follow-up: repeat assessments at about 3, 6 and 12 months, preferably by the same therapists, to compare objectively.
- Caregiver observations: we also ask families to keep brief notes on daily routines, such as feeding, transfers, sleep and communication, because changes in daily life complement formal scores.
- Outcome tracking: rather than relying on a single clinic-wide percentage, progress is measured against each patient's baseline using GMFM scores, therapist assessments, videos and daily-function goals. This gives families a more useful picture of whether meaningful change is occurring over time.
Safety in brief
Clinical studies of IV umbilical cord MSCs in children with CP report temporary fever, irritability, headache or fatigue as the most common effects, without serious treatment-related adverse events in the controlled trial described above. Safety depends on individual factors such as seizure control, breathing, swallowing and sedation needs. No treatment is free of risk, and the medical team reviews each child's situation before treatment. For children with epilepsy, fever after an infusion can lower the seizure threshold, so anti-seizure medications are never skipped and temperature is closely monitored.
Why rehabilitation strengthens the treatment plan
According to the CDC, effective CP care includes early intervention, physical, occupational and speech therapy, medications for spasticity and seizures, orthotics, assistive technology and surgery when needed. Cell therapy, when used, adds to these treatments and should not delay or replace them.
Warning signs when comparing clinics
Be cautious if a clinic:
- Promises improvements in speech, cognition or walking for every patient.
- Reports high success rates without published data.
- Says the treatment is risk-free or does not ask about seizures and sedation.
- Suggests reducing therapy or medications after treatment.
What our patients usually receive
Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:
- Wharton's jelly MSCs by IV infusion, with the number of cells adjusted to body weight and confirmed after the doctor reviews the medical reports.
- One night at our facilities, sometimes two, with nursing and medical monitoring and a parent or caregiver present.
- Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
- Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.
Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.
Questions to ask during your evaluation
- Which specific goals are realistic for my child?
- Which scales will be used to measure change, and when?
- How does my child's age and GMFCS level affect expectations?
- What dose and number of infusions are proposed, and why?
- How will treatment be coordinated with our therapy program?
Bottom line
Stem cell therapy for cerebral palsy has shown measurable improvements in motor function and daily activities in randomized studies, with a reassuring short-term safety profile. The most useful way to approach treatment is to pair the biological intervention with consistent rehabilitation, clear functional goals and objective measurement over time. A medical evaluation can help determine how this type of regenerative treatment may fit your child's or your own condition, goals and medical history.
References
- Gu J et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Research & Therapy, 2020 (opens in a new tab)
- Eggenberger S et al. Stem cell treatment and cerebral palsy: systemic review and meta-analysis. World Journal of Stem Cells, 2019 (opens in a new tab)
- Sun JM et al. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, placebo-controlled trial. Stem Cells Translational Medicine, 2017 (opens in a new tab)
- U.S. Centers for Disease Control and Prevention (CDC): Treatment and intervention for cerebral palsy (opens in a new tab)
- Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
